Search
Search Results
##search.searchResults.foundPlural##
-
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2929PDF: 876HTML: 6598Untitled: 254Untitled: 206Untitled: 230Untitled: 235 -
-
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1314PDF: 789HTML: 349 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1223PDF: 777HTML: 1527Figure 1: 209Figure 2: 204 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2637PDF: 821HTML: 5357 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3726PDF: 919HTML: 6857 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1880PDF: 1189HTML: 331 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1857PDF: 845HTML: 245 -
SIMPLE PERIPHERAL BLOOD SMEAR FINDINGS OF COVID-19 PATIENTS PROVIDE INFORMATION ABOUT THE SEVERITY OF THE DISEASE AND THE DURATION OF HOSPITAL STAY. Peripheral blood smear and COVID-19 severity.
3481PDF: 1208HTML: 488 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3059PDF: 1614HTML: 356 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
4027PDF: 767HTML: 1882 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2177PDF: 1576HTML: 636 -
GROUP-BASED TRAJECTORY MODELING OF PLATELET IN PATIENTS WITH APLASTIC ANEMIA: A STUDY BASED ON THE MIMIC DATABASE
1048PDF: 1045Suppl. Files: 654HTML: 176 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7752PDF: 2460HTML: 2101Table 1.: 233Table 2.: 242Table 3.: 224Table 4.: 218 -
The significance of purity: Leukaemias involving the erythroid lineage Erythroid lineage leukemia
857PDF: 433HTML: 313 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2402PDF: 1689HTML: 427 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2694PDF: 768HTML: 2320 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1469PDF: 1355HTML: 111 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1621PDF: 1071HTML: 412 -
TREATMENT OF CANCER IN THE OLDER AGED PERSON
1227PDF: 856HTML: 3412 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1563PDF: 1116HTML: 258 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2169PDF: 1339HTML: 3508 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1306PDF: 1052HTML: 399 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
1112PDF: 560Suppl. Files: 134HTML: 377







